Jongwoo Park

Title: Jongwoo Park: Innovator in HIV-1 Research

Introduction: Jongwoo Park is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of HIV research, particularly in the development of antiviral compounds. His innovative work focuses on creating small-molecule mimics that target critical components of the HIV-1 envelope protein.

Latest Patents: Jongwoo Park holds a patent for "CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof." This patent describes small-molecule mimics of CD4 that enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. The compounds developed exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, these compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, which is a significant advantage over NBD-556.

Career Highlights: Throughout his career, Jongwoo Park has focused on innovative solutions to combat HIV infection. His research has led to advancements in understanding how to inhibit the transmission and progression of HIV, contributing to the broader field of antiviral drug development.

Collaborations: Jongwoo Park has collaborated with notable researchers in the field, including Joseph G Sodroski and Judith M LaLonde. These collaborations have further enhanced the impact of his research and the development of effective antiviral strategies.

Conclusion: Jongwoo Park's work in developing CD4-mimetic inhibitors represents a significant advancement in HIV research. His innovative approach and dedication to combating this global health issue highlight the importance of continued research and collaboration in the field of antiviral therapies.